Recent 8-K filings for NBIX

• May 18, 2026 13:04 UTC m_and_a materiality 0.85 neutral item 1.01item 2.03item 2.01item 7.01item 9.01

  Neurocrine completes $2.9B acquisition of Soleno Therapeutics, adds VYKAT XR for Prader-Willi

  Tender offer accepted 46.4M shares (88.9% of Soleno) at $53/sh cash; total equity value ~$2.9B.

• May 05, 2026 23:59 UTC earnings materiality 0.90 positive item 2.02item 9.01

  Neurocrine Biosciences reports Q1 2026 sales $811M (up 44%); agrees to acquire Soleno Therapeutics for $2.9B

  Net product sales of $811.0M in Q1 2026, a 44% increase year-over-year, led by INGREZZA ($656.9M) and CRENESSITY ($153.3M).

• Apr 06, 2026 23:59 UTC m_and_a materiality 0.85 neutral item 1.01item 7.01item 9.01

  Neurocrine to acquire Soleno Therapeutics for $53.00 per share in cash

  Tender offer for all Soleno shares at $53.00 cash each; no financing condition.

• Feb 11, 2026 23:59 UTC earnings materiality 0.75 positive item 2.02item 9.01

  Neurocrine reports Q4 2025 revenue $805.5M, EPS $1.48 GAAP; guides INGREZZA 2026 sales $2.7-2.8B

  Q4 total net product sales $798.3M (+29% YoY); full year $2.83B (+22% YoY).

• Oct 28, 2025 23:59 UTC earnings materiality 0.80 positive item 2.02item 9.01

  Neurocrine Q3 net product sales $790M (+28% YoY); INGREZZA $687M (+12%); CRENESSITY $98M

  GAAP EPS $2.04 (diluted) vs $1.24 YoY; Non-GAAP EPS $2.17 vs $1.81; net income $209.5M.

• Jul 30, 2025 23:59 UTC earnings materiality 0.75 neutral item 2.02item 9.01

  Neurocrine Biosciences Q2 2025: Revenue $687.5M up 16.5% YoY; valbenazine Phase 3 schizophrenia miss

  Total revenue $687.5M; INGREZZA $624.4M (+8% YoY), CRENESSITY $53.2M (launch year).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

3 positive 0 negative 6 neutral

source · NBIX on sec.gov